Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Sales: 2020-2025

Historic Return on Sales for Kymera Therapeutics (KYMR) over the last 5 years, with Jun 2025 value amounting to -422.41%.

  • Kymera Therapeutics' Return on Sales fell 42031.00% to -422.41% in Q2 2025 from the same period last year, while for Jun 2025 it was -422.41%, marking a year-over-year decrease of 42031.00%. This contributed to the annual value of -84.48% for FY2024, which is 8237.00% down from last year.
  • According to the latest figures from Q2 2025, Kymera Therapeutics' Return on Sales is -422.41%, which was down 2,162.05% from -18.67% recorded in Q1 2025.
  • Kymera Therapeutics' Return on Sales' 5-year high stood at -0.91% during Q2 2021, with a 5-year trough of -422.41% in Q2 2025.
  • Moreover, its 3-year median value for Return on Sales was -3.49% (2023), whereas its average is -54.52%.
  • Its Return on Sales has fluctuated over the past 5 years, first surged by 426bps in 2021, then tumbled by 42,031bps in 2025.
  • Kymera Therapeutics' Return on Sales (Quarterly) stood at -1.38% in 2021, then tumbled by 206bps to -3.45% in 2022, then soared by 134bps to -2.11% in 2023, then crashed by 8,237bps to -84.48% in 2024, then crashed by 42,031bps to -422.41% in 2025.
  • Its Return on Sales was -422.41% in Q2 2025, compared to -18.67% in Q1 2025 and -84.48% in Q4 2024.